• Global lipid contract manufacturing market size was valued at USD 753 million in 2024 and is projected to reach USD 699 million by 2032, exhibiting a negative CAGR of 1.1% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• Lipid contract manufacturing involves the outsourced production of lipidbased drug delivery systems, primarily liposomes and lipid nanoparticles (LNPs), which serve as protective carriers for therapeutic agents. These formulations enhance drug solubility, stability, and targeted delivery, with applications spanning oncology, genetic medicines, and vaccine development. The primary lipid components include phospholipids, pegylated lipids, ionizable lipids, and triglycerides, engineered to optimize drugefficacy.
Email: help@intelmarketresearch.com +91 9169164321
•Lipid Nanoparticles (LNPs)
•Solid Lipid Nanoparticles
•Nanoemulsions
•Others
Pharmaceuticals • Nutraceuticals • Cosmetics • Research & Development • Others
• Merck KGaA (Germany)
• Exelead (U.S.)
• Avanti Polar Lipids (U.S.)
• Precision NanoSystems (Canada)
• Evonik (Germany)
• Genevant Sciences (Switzerland)
• Polymun Scientific (Austria)
Email: help@intelmarketresearch.com +91 9169164321
